In an open-label single-centre trial of 83 adults with obstructive mechanical prosthetic valve thrombosis, tenecteplase achieved complete thrombolytic success more often than low-dose slow-infusion alteplase (97.5% vs 81.5%; RR 1.18, noninferior), with similar adverse events.
RCTn = 83
Sharma et al. Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis: The TENET Randomized Clinical Trial